quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:00:00·6d
PRRelease
MiNK Therapeutics Inc. logo

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

INKT· MiNK Therapeutics Inc.
Health Care
Original source

Companies

  • INKT
    MiNK Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 15UpdateH.C. Wainwright$35.00
  • Jul 14UpdateWilliam Blair-
  • Jan 24UpdateB. Riley Securities$10.00
  • Nov 9UpdateB. Riley Securities$24.00
  • Nov 9UpdateRobert W. Baird$26.00
  • Nov 9UpdateWilliam Blair-

Related

  • INSIDER14d
    SEC Form 3 filed by new insider Orilall Melissa
  • PR21d
    MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
  • PR22d
    MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
  • PR23d
    MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
  • SEC23d
    SEC Form 10-K filed by MiNK Therapeutics Inc.
  • SEC24d
    MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR24d
    MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
  • SEC27d
    MiNK Therapeutics Inc. filed SEC Form 8-K: Other Events
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022